Last reviewed · How we verify
BAY2253651
BAY2253651 is a small molecule that targets the CDK9 protein.
BAY2253651 is a small molecule that targets the CDK9 protein. Used for Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | BAY2253651 |
|---|---|
| Sponsor | Bayer |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CDK9 is a crucial component of the positive transcription elongation factor b (P-TEFb) complex, which plays a key role in the regulation of RNA polymerase II-mediated transcription. By inhibiting CDK9, BAY2253651 aims to suppress the expression of oncogenic genes and induce apoptosis in cancer cells.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |